Trinity Biotech (NASDAQ:TRIB) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report sent to investors on Thursday. The firm issued a buy rating on the stock.

Trinity Biotech Stock Up 2.4 %

TRIB opened at $2.13 on Thursday. The firm has a market cap of $16.23 million, a price-to-earnings ratio of -0.76 and a beta of 1.16. The company’s 50-day moving average price is $1.96 and its 200 day moving average price is $2.15. Trinity Biotech has a fifty-two week low of $1.49 and a fifty-two week high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings results on Thursday, May 23rd. The company reported ($0.37) EPS for the quarter. Research analysts anticipate that Trinity Biotech will post -2.17 earnings per share for the current year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.